Prophylaxis Against Postoperative Nausea and Vomiting After Laparoscopic Cholecystectomy

Sponsor
Tanta University (Other)
Overall Status
Recruiting
CT.gov ID
NCT06017167
Collaborator
(none)
70
1
2
12.5
5.6

Study Details

Study Description

Brief Summary

The aim of the study is to compare antiemetic effects between dexmedetomidine and ondansteron in the first group versus dexamethasone and ondansteron in the second group.

The primary outcome in this study is incidence of postoperative nausea and vomiting after laparoscopic cholecystectomy.

The secondary outcomes are:
  • The severity of post operative nausea and vomiting.

  • Use of rescue antiemetic drugs.

  • Postoperative pain and sedation.

Condition or Disease Intervention/Treatment Phase
  • Drug: Ondansetron 4mg + dexmedetomidine 0.5 ug/kg + normal saline .
  • Drug: Ondansetron 4mg + dexamethasone 8mg + normal saline.
Phase 2

Detailed Description

General anesthesia is widely used in several surgeries. It can cause some complications such as postoperative nausea and vomiting (PONV). PONV is more common in general anesthesia than spinal anesthesia. PONV remains an extremely significant challenge due to its complex mechanism, resulting in serious consequences. Therefore an effective way to prevent or arrest PONV is urgently needed as Also, it can cause electrolyte imbalance and aggravate bleeding that delay hospital discharge.

The causes of PONV are multifactorial and can largely be categorized as patient risk factors, anaesthetic technique, and surgical procedure. Antiemetics work on several different receptor sites to prevent or treat PONV.

No single antiemetic pharmaceutical has been provided to be a universal solution to PONV. In general, multimodal combination treatment has superior viability for PONV prophylaxis compared with monotherapy .

Because nausea and vomiting were defined as two separate phe-nomena, studies should report and evaluate the variables distinctly . While since few patients experience vomiting without nausea, the incidence of PONV and postoperative nau¬sea (PON) is fairly similar, thus original papers often do not try to distinguish these variables . So, if PONV but not PON was reported in trails, we considered the PONV variables as a very close substitute for PON; when both PONV and PON were reported simultaneously, we assessed the nausea values. The most com¬monly used time interval to measure the role of antiemetic is 24 hours 6.

Ondansetron is a serotonin receptor antagonist, which is very important in preventing nausea and vomiting due to surgery and chemotherapy; it exhibited an anti-vomiting effect by inhibiting 5-Hydroxytryptamine type 3 (5-HT3) receptors in the vomiting centre .

Dexmedetomidine is a potent and highly selective a2-adrenoceptor agonist, which binds to transmembrane G protein-binding receptor located in the brain and spinal cord. Since nausea and vomit¬ing may be induced by high catecholamine con¬centrations, a decrease of sympathetic tone could explain the antiemetic effect of dexme¬detomidine. Finally, consumption of intraopera¬tive opioids, which increases the risk of PONV , may be reduced through the use of dexmedetomidine It affects the functions of central nervous, circulatory systems and exhibits sedative, analgesic, sympatholytic properties. Recently, the effect of dexmedetomidine on PONV has been the focus of clinical researchers. Nevertheless, controversy about the effectiveness of dexmedetomidine for PONV is still ongoing, for different results reported in associated literature.

Glucocorticoids may exert an antiemetic effect by inhibiting inflammatory mediators and by interacting with serotonin, neurokinin, a-adrenergic receptors, and other receptors. Furthermore, several studies have shown that dexamethasone enhances the antiemetic efficacies of 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
70 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Patients will be randomly classified with computer generated random numbers into two equal groups (each group 35 patients) Group I: will receive Ondansetron 4mg + dexmedetomidine 0.5 ug/kg + normal saline to complete 10 ml. volume IV infusion over 10 minutes. Group II: will receive Ondansetron 4mg + dexamethasone 8mg + normal saline to complete 10 ml volume IV ifusion over 10 minutes.Patients will be randomly classified with computer generated random numbers into two equal groups (each group 35 patients) Group I: will receive Ondansetron 4mg + dexmedetomidine 0.5 ug/kg + normal saline to complete 10 ml. volume IV infusion over 10 minutes. Group II: will receive Ondansetron 4mg + dexamethasone 8mg + normal saline to complete 10 ml volume IV ifusion over 10 minutes.
Masking:
Double (Participant, Outcomes Assessor)
Masking Description:
Double (Participant, Outcomes Assessor) The participants will be kept blind in both groups. Outcome assessors will be blinded as they will be anesthesia resident and nurse not participating in the study.
Primary Purpose:
Treatment
Official Title:
Dexmedetomidine Versus Dexamethasone Adding to Ondansetron for Prophylaxis Against Postoperative Nausea and Vomiting After Laparoscopic Cholecystectomy
Actual Study Start Date :
Sep 15, 2022
Anticipated Primary Completion Date :
Sep 1, 2023
Anticipated Study Completion Date :
Oct 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Dexmedetomidine Group

will receive ondansetron 4mg + dexmedetomidine 0.5 ug/kg + normal saline to complete 10 ml. volume IV infusion over 10 minutes.

Drug: Ondansetron 4mg + dexmedetomidine 0.5 ug/kg + normal saline .
compare antiemetic effects between dexmedetomidine and ondansetron in the first group versus dexamethasone and ondansetron in the second group
Other Names:
  • ondansetron 4mg (Zofran; GlaxoSmithKline, Alexandria, USA
  • dexmedetomidine (Precedex; Ho-Spira Inc., Lake Forest, Illinois, USA
  • Active Comparator: Dexamethasone Group

    will receive Ondansetron 4mg + dexamethasone 8mg + normal saline to complete 10 ml. volume IV infusion over 10 minutes.

    Drug: Ondansetron 4mg + dexamethasone 8mg + normal saline.
    Group II: Ondansetron 4mg + dexamethasone 8mg + normal saline.
    Other Names:
  • ondansetron 4mg (Zofran; GlaxoSmithKline, Alexandria, USA
  • dexamethasone; Amriya Pharmaceutical Industries, Egypt
  • Outcome Measures

    Primary Outcome Measures

    1. The incidence of postoperative nausea and vomiting after laparoscopic cholecystectomy. [through out 24 hours after surgery.]

      The incidence of vomiting, use of rescue antiemetics, and analgesic requirements were recorded at 0 to 1 hours after surgery in the postanesthetic care unit (PACU)At 6 and 24 hours after surgery, the incidence and severity of PONV were assessed using the Rhodes Index of nausea, vomiting, and retching.

    Secondary Outcome Measures

    1. The severity of post operative nausea and vomiting. [During 24 hours after surgery.]

      The severity of nausea was evaluated using a 10-point numerical rating scale (NRS) At 6 and 24 hours after surgery, the incidence and severity of PONV were assessed using the Rhodes Index of nausea, vomiting, and reteching.At 6 and 24 hours after surgery. The Rhodes Index is a reliable and valid patient self-reporting tool to assess nausea, vomiting, and retching and consists of eight items with 5 scales (0-4). This index has been shown to be a highly reliable method for evaluating gastrointestinal distress after ambulatory surgery.

    2. - Postoperative pain [During 24 hours after surgery.]

      Pain score was also assessed using a 10-point NRS.

    3. - Postoperative sedation [During 24 hours after surgery.]

      Ramsay sedation score (1=agitated, anxious, or restless; 2=oriented, cooperated, and tranquil; 3=responsive to verbal commands only; 4=asleep, brisk response to a loud auditory stimulus or a light glabella tap; 5=sluggish response to a glabella tap or loud auditory stimulus; 6=no response to a loud auditory stimulus or a light glabella tap) were recorded. Over-sedation was defined as a Ramsay sedation score>4.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 65 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • 70 Female patients aged between 18 and 65 years

    • ASA I or II

    • patients scheduled for elective laparoscopic cholecystectomy surgery will be included in this study.

    Exclusion Criteria:
    • Females above 65 years old.

    • patients under 18 years old.

    • ASA > II.

    • Obesity (BMI>40 kgm2).

    • Known hypersensitivity to drugs used in the study protocol.

    • Comorbidities that were known to increase the risk of PONV (e.g. vestibular disease).

    • Liver or renal dysfunction (liver enzyme or creatinine 1.5 times higher than normal).

    • Alcoholism or drug abuse.

    • Use of antiemetics and psychotropic drugs or glucocorticoids within 24 h before surgery.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Tanta University hospitals Tanta Algharbia Egypt 31511

    Sponsors and Collaborators

    • Tanta University

    Investigators

    • Principal Investigator: Mohamed A. Lotfy, PHD, Assistant Professor of Anesthesia and Intensive Care, Tanta Univ

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    yasmine mohammed mahmoud mustafa eldeba, Resident doctor of Anaesthesia and ICU Department, Tanta University
    ClinicalTrials.gov Identifier:
    NCT06017167
    Other Study ID Numbers:
    • PONV after lap cholecystectomy
    First Posted:
    Aug 30, 2023
    Last Update Posted:
    Aug 30, 2023
    Last Verified:
    Aug 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by yasmine mohammed mahmoud mustafa eldeba, Resident doctor of Anaesthesia and ICU Department, Tanta University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 30, 2023